Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Severe Persistent Asthma
Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
The overall purpose of the trial is to evaluate efficacy and safety of tiotropium inhalation
solution (2.5 mcg and 5 mcg) delivered via Respimat® inhaler once daily in the evening over
12 weeks, compared to placebo, as add-on controller therapy on top of usual care in children
(6 to 11 years old) with severe persistent asthma.